{"name":"Pliant Therapeutics, Inc.","slug":"pliant","ticker":"PLRX","exchange":"NASDAQ","domain":"pliantrx.com","description":"Pliant Therapeutics, Inc. is a biotechnology company focused on developing anti-fibrotic therapies. Their top drugs include PLN-74809, a selective inhibitor of the TGF-β type III receptor, and PLN-1011, a selective inhibitor of the TGF-β type I receptor. The company is positioned to address significant unmet needs in fibrotic diseases.","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"Bernard Coulie","sector":"Biotech — Anti-Fibrotic","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.1B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"PLN-74809 patent cliff ($1.4B at risk)","drug":"PLN-74809","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"PLN-1011 patent cliff ($2.1B at risk)","drug":"PLN-1011","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Pliant Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Pliant Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting progress in its anti-fibrotic pipeline.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Pliant Therapeutics Announces Collaboration with AbbVie to Develop Anti-Fibrotic Therapies","summary":"Pliant Therapeutics announced a collaboration with AbbVie to develop anti-fibrotic therapies for various indications.","drugName":"","sentiment":"positive"},{"date":"2023-09-12","type":"trial","headline":"Pliant Therapeutics Presents Positive Phase 2a Results for PLN-74809 in Idiopathic Pulmonary Fibrosis","summary":"Pliant Therapeutics presented positive Phase 2a results for PLN-74809 in idiopathic pulmonary fibrosis, demonstrating significant efficacy.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5qUUdvdE5DWVY3OTBRNVFqcnhqcGZ6LTZBT0NveXBvMmFVQWRzYWhtb3k4SGIzMjFRcUc5Mmd4MjNubmpTXzBtbXl3Wl92MzFRdmh3dGNZR19DRE0xV2ZsR1JmdGt0ZjFBclZvcGlR?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Pliant Therapeutics, Inc. (PLRX) - Stock Titan","headline":"If You Invested $1,000 in Pliant Therapeutics, Inc. (PLRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxOdm90RzFBMHJuOEwya29VbGhyb2dLMTRscWFmSzdjN0F2LVpGMENiYVE5MXZRbXIxdVNJMU84VXdQY04yREFZbkE4QmVjdlkxTVZEZzdSSF9xYzF1SGl4aDBRV2N3OW9qNU5uNzFRa09LZUJkWWVrQlJ0VHVPR0dnMFRmMDBQOF82ZTlKak94WUhCelhNeFFIa0ZkdlhzUHl4c3VEUlotWUxiMmxnNndhQUY2QVQ4TWxMeTRycTFIbFFqVlpMcHg3b0IwUE9Ya19hSmUwaElxaGdNWDNDRk5CVUxzb0N3R3p5dXQ1c21sanYzYXhWSmpJenkwUGxqUHRMTlpDMy1JYl9KV3B2dTZtU29kdzg4LXNaLXNWRkdGemZoa19pQTQ5aWlNbE50MmZwMFhfdlduZ3VlZVZ1Qk1WaV9VcVBLal9JaWN5U2VwMFdVLUl0?oc=5","date":"2026-02-26","type":"regulatory","source":"Barchart","summary":"Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics ","headline":"Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsig","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMVF4ajR2Y0h1NWN0bzV1T3dXR0ItS3NsbnMwaDFYRjQwM1hWNFBLUWhyeFVMR01nYTZCZHM1UFlkbXhNMkRJMi1zQnlkQXlHUzRvV2cwR2NyOVhLb0V0RFJNdTF2VzJ0UkIyRDdVakdXTzhqbzR4RkdlcnVhNWZaTmVEMFdxTTB3T0pOQU1ZSldNbW1NV1lyVUJaOGRpemNKbkoxQzJ6OXlZNTR6d25JdHROXzkyOENZMlN0ZmRqQk4?oc=5","date":"2026-02-24","type":"patent","source":"Seeking Alpha","summary":"Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration - Seeking Alpha","headline":"Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-08","type":"pipeline","source":"simplywall.st","summary":"Penny Stocks To Watch With Market Caps Under $700M - simplywall.st","headline":"Penny Stocks To Watch With Market Caps Under $700M","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-15","type":"pipeline","source":"simplywall.st","summary":"3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st","headline":"3 Promising Penny Stocks With Market Caps Under $200M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQcEtkbWt0WTlBMWpLTTJZZkhvUjdGYzBXNTB0WWtxSHU1Y2o2ZTkwSlgtZENJY1lxREZSTWh5OUZIQmlsSUpBN04tOFo1bHNCRHFoaGFQWGtzemMzZHA2Zi1MaVl0Y2FyeEJwUmQ2UGhCRklRNjZJUVRyWGRpbm5FdmdpSE9UTmlCR212Q285S3ZtRm4tTDBWNmU3RjA2Q3N4ZGQ1QmUwWnFzQnNxVU9Tczktd2I2QVk?oc=5","date":"2025-07-02","type":"pipeline","source":"Seeking Alpha","summary":"From Nebius Group To EOS: A Strong Year And What’s Next For Our Family Office (NBIS) - Seeking Alpha","headline":"From Nebius Group To EOS: A Strong Year And What’s Next For Our Family Office (NBIS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5PZVZjRkZvM0k3VkJLWmtsYWR0VVhPU0t4amx1eWotbklQVGE0RDU1MS0wNE95QktUWnFrNWtLNFpqcnhwWGxCTEhaMVZmQ3c5T2xR?oc=5","date":"2025-07-02","type":"pipeline","source":"Stock Titan","summary":"PTHS Stock Price, News & Analysis - Stock Titan","headline":"PTHS Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1wRnI5aGpSTVhSa2gxSXFnN2Z5S3BBX3Blam9iWmcxWlpkZXRYdHJmeHFQdjNNVTh5NnFZc085dkhSRzFPODhuT2l6YTJjazN2dF9z?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"MEIP Stock Price, News & Analysis - Stock Titan","headline":"MEIP Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5NMUpyRFE1UTh6RTFFSHRoWEp0eUFsaUJVWGFrMGhobHJrVmhLMEYyb09oa0ppSDZ0Qm9PQlZfUmdKNkNJQV9jOUZ6dG1mZ2Y3MnQ1ZXZfcHdnZ2Ffa01sM29pel9xVFBxcjVvTGlOVW9IZ0pqS0pzbHhB?oc=5","date":"2023-05-18","type":"earnings","source":"Investopedia","summary":"Top Pharmaceutical Stocks for Q2 2023 - Investopedia","headline":"Top Pharmaceutical Stocks for Q2 2023","sentiment":"neutral"}],"patents":[{"drugName":"PLN-74809","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"PLN-1011","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":2100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["United Therapeutics","Bristol Myers Squibb","Gilead Sciences"],"therapeuticFocus":["Idiopathic Pulmonary Fibrosis","Liver Fibrosis"],"financials":null,"yahoo":null}